Kathmere Capital Management LLC Purchases 16,724 Shares of Pfizer Inc. $PFE

Key Points

• Kathmere Capital Management LLC significantly increased its holdings in Pfizer Inc. by 174.9%, purchasing an additional 16,724 shares, bringing its total to 26,288 shares valued at $637,000.
• In the same period, other institutional investors such as ST Germain D J Co. Inc. and New Insight Wealth Advisors also boosted their stakes in Pfizer, indicating strong interest from large investors.
• Pfizer reported $0.78 earnings per share (EPS) for the last quarter, exceeding analysts' expectations and showing a revenue growth of 10.3% year-over-year.

Kathmere Capital Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 174.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,288 shares of the biopharmaceutical company's stock after buying an additional 16,724 shares during the period. Kathmere Capital Management LLC's holdings in Pfizer were worth $637,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. ST Germain D J Co. Inc. boosted its holdings in shares of Pfizer by 19.8% during the 2nd quarter. ST Germain D J Co. Inc. now owns 28,373 shares of the biopharmaceutical company's stock worth $688,000 after buying an additional 4,694 shares during the period. FCG Investment Co acquired a new position in Pfizer during the 2nd quarter valued at $356,000. New Insight Wealth Advisors raised its stake in Pfizer by 23.3% during the 2nd quarter. New Insight Wealth Advisors now owns 167,834 shares of the biopharmaceutical company's stock valued at $4,068,000 after purchasing an additional 31,696 shares during the last quarter. BankPlus Wealth Management LLC raised its stake in Pfizer by 8.3% during the 2nd quarter. BankPlus Wealth Management LLC now owns 17,830 shares of the biopharmaceutical company's stock valued at $432,000 after purchasing an additional 1,371 shares during the last quarter. Finally, LS Investment Advisors LLC raised its stake in Pfizer by 12.1% during the 2nd quarter. LS Investment Advisors LLC now owns 90,179 shares of the biopharmaceutical company's stock valued at $2,186,000 after purchasing an additional 9,727 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.6%

Shares of PFE stock opened at $23.75 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock has a market cap of $135.03 billion, a price-to-earnings ratio of 12.63, a P/E/G ratio of 0.77 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a fifty day moving average of $24.55 and a 200-day moving average of $24.13.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 EPS. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.